ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

IMNN Imunon Inc

1.0601
-0.0099 (-0.93%)
Última actualización: 11:03:40
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Imunon Inc IMNN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0099 -0.93% 1.0601 11:03:40
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.05 1.05 1.095 1.07
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/6/202405:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202405:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202405:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202405:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202405:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202405:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202405:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202408:00EDGAR2Form 8-K - Current report
10/6/202413:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/6/202407:30GLOBEFirst Participants Vaccinated in IMUNON’s IMNN-101 Phase 1..
20/5/202407:30EDGAR2Form 8-K - Current report
15/5/202415:16EDGAR2Form S-3 - Registration statement under Securities Act of..
15/5/202407:30GLOBEAbstract on Phase 2 Study with IMUNON’s IMNN-001 Plus..
14/5/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202408:00GLOBEIMUNON Announces Site Activation for IMNN-101 Phase 1..
13/5/202407:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202407:05EDGAR2Form 8-K - Current report
13/5/202407:00GLOBEIMUNON Reports First Quarter 2024 Financial Results and..
08/5/202407:15EDGAR2Form 8-K - Current report
08/5/202407:00GLOBEIMUNON Appoints Director Dr. Stacy R. Lindborg as President..
06/5/202410:00GLOBEIMUNON to Hold First Quarter 2024 Financial Results and..
18/4/202407:30GLOBEIMUNON’s IND Application Cleared to Begin Human Testing of..
11/4/202407:00GLOBEIMUNON Reports Compliance with Nasdaq Listing Requirements
28/3/202407:00GLOBEIMUNON Reports 2023 Financial Results and Provides Business..
25/3/202407:30GLOBEIMUNON Receives $1.3 Million from Sale of its New Jersey Net..
21/3/202416:00GLOBEIMUNON to Hold 2023 Financial Results and Business Update..
13/3/202407:00GLOBEIMUNON Files IND Application to Begin Human Testing of..
12/3/202416:00GLOBEIMUNON Announces Leadership Change
29/2/202407:30GLOBEIndependent Lab Confirms Immunogenicity and Protection with..
27/2/202407:30GLOBEMemorial Sloan Kettering Cancer Center Now Enrolling..
22/2/202407:00GLOBEIMNN-101 Preclinical Data in SARS CoV-2 Published in..
09/2/202415:09EDGAR2Form S-1/A - General form for registration of securities..
29/12/202315:30EDGAR2Form 8-K - Current report
20/12/202316:15EDGAR2Form S-1 - General form for registration of securities under..
11/12/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202307:35EDGAR2Form 8-K - Current report
11/12/202307:30GLOBEIMUNON Appoints Dr. Sebastien Hazard as Chief Medical..
14/11/202308:00GLOBEIMUNON’s VP of R&D to Present at the Vaccines Summit-2023
14/11/202307:00GLOBEIMUNON Reports Third Quarter 2023 Financial Results and..
07/11/202307:30GLOBEIMUNON to Hold Third Quarter 2023 Financial Results and..
23/10/202307:30GLOBEIMUNON’s Chief Science Officer to Present at the 3rd..
19/10/202307:30GLOBEIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel..
18/10/202307:30GLOBEIMUNON Announces First Patient enrolled in Phase 1/2..
06/10/202307:30GLOBEIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory..
28/9/202307:30GLOBEIMUNON Reports Interim Progression-Free Survival and Overall..
26/9/202307:30GLOBEIMUNON Releases Enterprise Video Highlighting the Company’s..
13/9/202307:30GLOBEIMUNON Reminds Investors of its Virtual R&D Day Tomorrow at..
07/9/202315:30GLOBEIMUNON to Host Virtual R&D Day on September 14th Beginning..
05/9/202307:30GLOBEIMUNON to Participate in the H.C. Wainwright Global..
24/8/202315:05GLOBEIMUNON Enters into CRADA for Preclinical Studies of PlaCCine..

Su Consulta Reciente

Delayed Upgrade Clock